Stockscreener 앱 받기
118.25
1.26%
1.47
시장 영업 전:
118.20
-0.05
-0.04%
전일 마감가:
$116.78
열려 있는:
$117.11
하루 거래량:
6.50M
Relative Volume:
1.01
시가총액:
$146.73B
수익:
$28.80B
순이익/손실:
$6.31B
주가수익비율:
23.52
EPS:
5.0273
순현금흐름:
$9.37B
1주 성능:
+6.39%
1개월 성능:
+2.05%
6개월 성능:
+14.59%
1년 성능:
+38.77%
1일 변동 폭
$115.75
$118.35
1주일 범위
$108.46
$118.35
52주 변동 폭
$84.17
$121.83
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
GILD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
118.25 | 144.90B | 28.80B | 6.31B | 9.37B | 5.0273 |
|
LLY
Lilly Eli Co
|
845.72 | 756.28B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
189.69 | 454.91B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
231.24 | 411.31B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
132.31 | 254.66B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
86.40 | 218.83B | 63.43B | 16.42B | 14.72B | 6.4861 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Kingswood Wealth Advisors LLC Reduces Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Given "Buy (B)" Rating at Weiss Ratings - MarketBeat
Gilead Sciences Rallies After Trump Partnership News Is the Growth Story Just Beginning - Yahoo Finance
GILD: Citigroup Raises Price Target for Gilead Sciences Amid Buy Rating | GILD Stock News - GuruFocus
Greed Is a Hell of a Drug - Truthdig
Multiple Myeloma CAR-T Market Set for Rapid Growth Driven by BCMA-Targeted Therapies and Innovative Advances - GlobeNewswire Inc.
RBC Capital raises Gilead Sciences stock price target to $100 on Yeztugo launch - Investing.com
Royal Bank Of Canada Increases Gilead Sciences (NASDAQ:GILD) Price Target to $100.00 - MarketBeat
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $135.00 at Citigroup - MarketBeat
Citigroup Adjusts Price Target on Gilead Sciences to $135 From $125, Maintains Buy Rating - MarketScreener
RBC Lifts Price Target on Gilead Sciences to $100 From $98, Keeps Sector Perform Rating - MarketScreener
WESPAC Advisors LLC Purchases 7,248 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Settlements Push Back US Biktarvy Competition To 2036 - insights.citeline.com
Triasima Portfolio Management inc. Increases Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Friedenthal Financial Purchases Shares of 9,152 Gilead Sciences, Inc. $GILD - MarketBeat
Valeo Financial Advisors LLC Boosts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
DAVENPORT & Co LLC Sells 16,332 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Sees Relative Strength Rating Rise To 72 - Investor's Business Daily
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years - Benzinga
Gilead Sciences stock rises as Bernstein reiterates Outperform rating - Investing.com
SteelPeak Wealth LLC Lowers Position in Gilead Sciences, Inc. $GILD - MarketBeat
KLP Kapitalforvaltning AS Purchases 20,100 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy - Zacks Investment Research
Going Beyond – Ending the HIV epidemic by 2030 : From Belgium to the EU - Gilead Sciences
Shell Asset Management Co. Buys 22,026 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead inks trio of Biktarvy patent settlements, waylaying US copycats until 2036 - Fierce Pharma
Gilead Sciences 2025: Slow and steady - PharmaLive
Simplicity Wealth LLC Boosts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by Merit Financial Group LLC - MarketBeat
Gilead Sciences Settles Patent Litigations With Generic Drugmakers For Best-Selling HIV Drug: Analyst Cheers Longer Runway - Stocktwits
Gilead Gets HIV Generic Drugs Barred From Market Until 2036 - Law360
Gilead Scores A 'Solid Win' For Its Biggest Moneymaker; Shares Jump - Investor's Business Daily
Gilead (GILD) Reaches Settlement in HIV Treatment Patent Lawsuit - GuruFocus
Gilead, Cipla Settlement Blocks Copies of Biktarvy HIV Drug - Bloomberg Law News
Gilead Reaches Settlement To Block Biktarvy Generics Until 2036Gilead Sciences (NASDAQ:GILD) - Benzinga
Gilead Shares Rise After Reaching Settlement on Biktarvy Patent Disputes - MSN
Gilead Sciences (GILD) Announces Settlement Agreements to Resolve Patent Litigations - GuruFocus
Gilead Sciences (GILD) Secures Patent Protection for Biktarvy Un - GuruFocus
Gilead Sciences settles patent litigations related to Biktarvy - MSN
Gilead (GILD) Resolves Patent Disputes Over Biktarvy - GuruFocus
Gilead Sciences Settles Patent Litigation on Biktarvy - TipRanks
Gilead stock rises after settling Biktarvy patent disputes By Investing.com - Investing.com Canada
Gilead stock rises after settling Biktarvy patent disputes - Investing.com
Needham reiterates Buy rating on Gilead stock, sees promise in inflammation pipeline - Investing.com
Gilead Sciences Inc announces settlement agreements with Lupin, Cipla and Laurus LabsSEC filing - MarketScreener
Gilead Sciences reaches settlement on Biktarvy patent litigation with generics - Investing.com
Gilead settles patent disputes over Biktarvy with generic drugmakers - StreetInsider
Gilead Sciences: Strategic Diversification and Promising Inflammation Pipeline Justify Buy Rating - TipRanks
Grimes & Company Inc. Has $17.44 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Valuation After Kymera Oncology Partnership and Revenue Growth Momentum - simplywall.st
AMF Tjanstepension AB Purchases 154,530 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.25%
1.00%
자본화:
|
볼륨(24시간):